Diaz Discusses the FDA Approval of Pembrolizumab for MSI-H Solid TumorsByLuis A. Diaz Jr, MDJuly 10th 2017Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.